PSMA-PRMT5i

PSMA-PRMT5i: sourced facts only. name: "PSMA-PRMT5i was found to bind PSMA on LNCaP cells in culture with high affinity (Kd = 1.5 nM) and significantly reduce their survival following exposure to 2Gy of beam radiation." [DOI:10.1158/1538-7445.am2025-590]; target: "PSMA-PRMT5i was found to bind PSMA on LNCaP cells in culture with high affinity (Kd = 1.5 nM) and significantly reduce their survival following exposure to 2Gy of beam radiation." [DOI:10.1158/1538-7445.am2025-590]; developer: "Purdue University, West Lafayette, IN." [DOI:10.1158/1538-7445.am2025-590]; stage: "Finally, analysis of antitumor activity in LNCaP tumor bearing mice demonstrated that the targeted PSMA-PRMT5i reduced tumor growth by 90% when used in combination with 177 Lu-Pluvicto, whereas 177 Lu-Pluvicto alone suppressed tumor growth by only 50%." [DOI:10.1158/1538-7445.am2025-590]